Immunotherapy advances for glioblastoma - Wikidata - thesis-toulmin - TriplyDB

Immunotherapy advances for glioblastoma

Immunotherapy advances for glioblastoma

http://www.wikidata.org/entity/Q26866513

about

Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines Ephs and Ephrins in malignant gliomas Prospects of immune checkpoint modulators in the treatment of glioblastoma Immunotherapy response assessment in neuro-oncology: a report of the RANO working group Bionanotechnology and the future of glioma.Immune Checkpoint in Glioblastoma: Promising and Challenging Single vs. combination immunotherapeutic strategies for glioma.Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma Cancer stem cells in glioblastoma Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.In search of druggable targets for GBM amino acid metabolism.The role of checkpoints in the treatment of GBM Current status and future directions of anti-angiogenic therapy for gliomas Glioma-derived extracellular vesicles selectively suppress immune responses.Epidermal growth factor receptor targeting and challenges in glioblastoma.Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Immunotherapy in glioblastoma: emerging options in precision medicine Recent advances and future of immunotherapy for glioblastoma.Induction of specific T helper-9 cells to inhibit glioma cell growth.Rindopepimut vaccine and bevacizumab combination therapy: improving survival rates in relapsed glioblastoma patients?The Dynamics of Interactions Among Immune and Glioblastoma Cells.Circulating biomarkers for gliomas.An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.Principles of immunology and its nuances in the central nervous system.Advances in the molecular genetics of gliomas - implications for classification and therapy.Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.Checkpoint inhibition in meningiomas.Anaplastic astrocytoma.Cellular immunotherapy for malignant gliomas.Concepts in glioma immunotherapy.Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma Advances and challenges: dendritic cell vaccination strategies for glioblastoma.The Safety of available immunotherapy for the treatment of glioblastoma.Role of AHR and HIF-1α in Glioblastoma Metabolism.Current update of adoptive immunotherapy using cytokine-induced killer cells to eliminate malignant gliomas.Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy.Detection of inflammatory cell function using (13)C magnetic resonance spectroscopy of hyperpolarized [6-(13)C]-arginine.Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival.Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas.Neutrophils in Gliomas.

P2860

Q26772715-DC144243-5C3F-44CD-9CAC-7AEA3EE7461D Q27015780-E091029A-DD87-4656-B81A-569009F26FD6 Q28081371-F13DE0AD-9406-4EEE-B981-A557892965D7 Q28083009-368897FC-02FF-4E30-A030-7D09FCB854ED Q30417964-BE173D60-9DD4-49A6-B061-DEAE5BEAC11B Q33650058-61CED562-7244-45EB-BD4E-6B08BA269921 Q33746041-8F6D1E29-5758-4CCA-9536-6405F7925BD9 Q35741539-94CA49F9-6324-4A2E-A5C0-6CF943E44ED6 Q35829972-634B96B7-6052-4411-AC61-C348AD4C6332 Q36266545-131E4F5E-A027-4955-8179-8A069B31C9B2 Q36293108-BCC40316-2735-48E2-B4CC-1F25C527BD01 Q36571197-682C37DF-9CA4-4E38-8945-FFBC82B1FF68 Q36618235-5FA41AB1-1566-4768-9ED3-164A6FB8C30F Q36705896-872EA566-4089-4229-9213-4FA3FE41086B Q36977684-BC884C60-A37E-4122-B4E9-26FBD4D57A72 Q37014134-2E160BF4-FAC4-418E-A832-68AE68C3A3E2 Q37050960-825D8014-2956-4112-BA24-F14124187672 Q37239071-705598E1-D809-4D7B-96EB-5C9BC0EF63E6 Q37706268-9DA0CD32-9AAA-4361-8F92-DAD1B28D8C82 Q38534723-EB3F5506-1E19-4FC1-BF09-66A711A800B9 Q38557236-8E497E22-53B7-4B76-897B-B27BAE0A4453 Q38586617-83FD466A-6FE8-4AE9-9FC4-30F171DC3A08 Q38603909-A6479DCD-3A57-4E5E-9981-4A169E0B3A92 Q38620084-331D3FD8-CD87-481E-A740-410044689CFB Q38777058-AACBB368-C2FD-4FBD-927E-67798D1143FF Q38823847-FED4FE6C-74AC-405C-874A-7976CC10D774 Q38838646-A1B4D91C-EEFC-4502-8FA7-A39B1048EB86 Q38845657-9E93101C-00CE-40A0-8DAF-574FF16990E0 Q38902169-E9E48B7A-C646-4C76-A0C9-F3C80AC29E0F Q38909071-EE4AFE67-B712-4F0B-9578-EF73061E5643 Q38912327-B4195D3C-D6E4-4A98-9097-297F2EA45DA7 Q38921652-C75C940D-1040-43EA-9EDD-D1BF4729BB49 Q39042442-536AFF4E-6FFC-4B6F-9A6C-1F17EE1822A0 Q39187735-E112A8B1-7759-4EE5-B300-1734E2B0D1CD Q39208487-74ECD729-BDFE-421D-A570-84835A384139 Q40982444-59EF65A9-7D0A-4CE5-8299-CE6B40244878 Q42368949-2FF0C8FD-31F3-4FEB-AD2D-D674DC01264E Q42639856-AB8AEFEE-1CD7-43C5-AB30-6A8D478772DC Q43290383-4644FCF1-FB82-4283-84C8-D5D5222919EB Q43749590-2F89FA04-CE5C-4A08-9B30-B68E67F85DD1

P2860

Immunotherapy advances for glioblastoma

http://www.wikidata.org/entity/Q26866513

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Immunotherapy advances for glioblastoma

@ast

Immunotherapy advances for glioblastoma

@en

Immunotherapy advances for glioblastoma

@nl

type

label

Immunotherapy advances for glioblastoma

@ast

Immunotherapy advances for glioblastoma

@en

Immunotherapy advances for glioblastoma

@nl

prefLabel

Immunotherapy advances for glioblastoma

@ast

Immunotherapy advances for glioblastoma

@en

Immunotherapy advances for glioblastoma

@nl

P1433

Q26866513-3E7BDC82-8C0B-4008-B995-123A0CD0C6E3

P1476

Q26866513-A53D7866-CCFF-4E82-8E64-6BB78FF91A86

P2093

Q26866513-05B7E949-0F5A-4A9F-908D-25C306A3ADE0

Q26866513-27C46ADF-8077-49E4-AA63-8B1ACD833A2C

Q26866513-28226A9F-5E03-41A8-9DB0-42B7C6DABB00

Q26866513-3071ADC1-026C-4C60-A549-3D31EAFB871B

Q26866513-371257B9-4F25-493F-AEF2-F88099FB0ED5

Q26866513-45A52D80-D67B-4555-9C8A-18D65A78B8FA

Q26866513-8FF0C50A-BDEA-4CA3-9E62-CE0D09D0D5B6

Q26866513-F381EAC6-9DCA-4043-BC52-7A016F2B8B22

Q26866513-F548084B-77FA-4F1A-BFD8-FAE344497F13

P2860

Q26866513-01312952-150F-47E3-B8C2-247C7ACF15D6

Q26866513-01DA176A-0564-48ED-8662-8B3235EF68D4

Q26866513-05036E1C-8454-4CED-B62C-A562B3106F4D

Q26866513-051B422B-716C-45F3-95E0-4FC6598485B5

Q26866513-061F3B39-B4C0-4F92-94AA-D6A0ED697621

Q26866513-0643743B-D4CF-443F-BDE2-1326BB7411F5

Q26866513-0644D1A1-8215-42D6-A8E0-C7F4FCB834BD

Q26866513-0820C6BA-5429-4F44-A7AF-472617759E40

Q26866513-0B2F3CB9-48BB-45CC-B989-2497CCDD0C29

Q26866513-0DDD148F-2011-4346-A23F-BB14CA6C8CDD

P304

Q26866513-3E00D578-5161-4C52-B5C6-51A6D57C84B0

P31

Q26866513-02FEBB4F-69F2-400D-99A8-F0DB32CA33B5

P3181

Q26866513-28E0E336-CA98-4060-BC33-C604DA4EDED4

P356

Q26866513-0EB8A0E5-4677-4C10-8F1E-91B537F35DA4

P407

Q26866513-59FEC858-BEFC-4359-82B5-20144DCBBD9A

P433

Q26866513-76122EEF-4D25-4CB6-A085-07C03D03576F

P478

Q26866513-36C1BA2B-3290-44F4-ADF3-5EC0DB8DDC78

P50

Q26866513-A560BCCB-AF74-45A2-81D0-D70DEC05DF79

P577

Q26866513-FB2D9482-E189-4AB8-837D-AC64CEC1E1A8

P5875

Q26866513-FCA8D870-D90C-4A3C-A132-06B6BAF850D8

P698

Q26866513-702A4E1B-0FEA-4C17-904B-07B79A077470

P921

Q26866513-5C056206-8BAE-4EE7-9993-800AB52C1531

P932

Q26866513-FADB482A-55AE-41D0-A1E2-BAE48AA46A09

P3181

P356

P1433

P1476

Immunotherapy advances for glioblastoma

@en

P2093

Catherine Wu

http://www.w3.org/2001/XMLSchema#string

David A Reardon

http://www.w3.org/2001/XMLSchema#string

E Antonio Chiocca

http://www.w3.org/2001/XMLSchema#string

Edward F Fritsch

http://www.w3.org/2001/XMLSchema#string

Glenn Dranoff

http://www.w3.org/2001/XMLSchema#string

Gordon Freeman

http://www.w3.org/2001/XMLSchema#string

Kai W Wucherpfennig

http://www.w3.org/2001/XMLSchema#string

Patrick Y Wen

http://www.w3.org/2001/XMLSchema#string

William T Curry

http://www.w3.org/2001/XMLSchema#string

P2860

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

CNS immune privilege: hiding in plain sight.

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.

Nivolumab plus ipilimumab in advanced melanoma.

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

P304

1441-1458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4169551

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/NEUONC/NOU212

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265393641

http://www.w3.org/2001/XMLSchema#string

P698

25190673

http://www.w3.org/2001/XMLSchema#string

P921

P932

4201077

http://www.w3.org/2001/XMLSchema#string